<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="117795">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02067169</url>
  </required_header>
  <id_info>
    <org_study_id>I09013 ORPHAVIC</org_study_id>
    <nct_id>NCT02067169</nct_id>
  </id_info>
  <brief_title>A French Cohort of Transplant Recipients With CMV Infection : Risk Factors for Antiviral Resistance in the Prophylaxis Era.</brief_title>
  <acronym>ORPHAVIC</acronym>
  <official_title>A French Cohort of Transplant Recipients With CMV Infection : Risk Factors for Antiviral Resistance in the Prophylaxis Era. Survey of Pharmacological and Virological Resistance of Cytomegalovirus to Antiviral Therapy in Transplantation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Limoges</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Limoges</source>
  <oversight_info>
    <authority>France: National Consultative Ethics Committee for Health and Life Sciences</authority>
    <authority>France: The Commission nationale de l’informatique et des libertés</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Resistance to antivirals is a growing problem in transplantation.that may concerns up to 5%
      of patients treated for cytomegalovirus (CMV) syndrome or disease in recent per-protocol
      studies. This prevalence vary with the organ transplanted and the degree of viral
      replication and immunosuppression. Less data are available to date from real-life cohorts of
      patients, and there is no systematic survey of resistance in Europe or in the US. Non
      response to treatment concerns a larger group of patients and can result either from
      emergence of a resistant strain (virological resistance), from inadequate dosage of
      antivirals, or a high degree of immunosuppression, with a poor CMV immune response. The
      respective clinical impact of virological resistance and clinical resistance (of
      pharmacological or immunological origin) on graft outcome and long-term survival of patients
      has never been assessed. High viral loads and persistent replication associated to prolonged
      exposure to antivirals are known to favor the emergence of resistant strains. Though
      epidemiology of resistant strains, role of multiple infections, impact of various mutations
      on degree of resistance to antivirals and outcome remains to be further studied. Most
      studies are per-protocol studies or short-term studies conducted on limited populations.
      There are no data in real-life of transplanted patients at the era of enlarged prophylaxis
      except those from the French survey for cytomegalovirus resistance cohort opened at the end
      of 2006. From the first data collected on 346 patients we shown a 10,6% prevalence of
      non-response to therapy with 5,2% of virological resistance (6,1% incidence at one year on
      214 patients) with a trend to poorer outcome in case of virological resistance and to the
      absence of impact of prophylaxis versus preemptive therapy, though larger populations and
      prolonged follow-up are requested to fulfill all objectives.

      We therefore aim to constitute a prolonged survey cohort for CMV resistance with a large
      number of patients and a prolonged follow-up, to gather data on resistance to antivirals in
      real-life of transplant patients in an organized data bank, This cohort is in the continuum
      of our previous cohort started in 2006, granted by the Hospital Clinical Research Program
      Interregional (PHRC), with the same major objectives and prolonged follow-up of patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">January 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>prevalence and incidence of resistance of cytomegalovirus</measure>
    <time_frame>3 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Non response to therapy is defined as persistent viral replication after more than 3 weeks of appropriate antiviral treatment, with or without clinical manifestations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pharmacological and virological resistance</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measure the respective incidence of pharmacological and virological resistance</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Transplant Recipients With CMV Infection</condition>
  <arm_group>
    <arm_group_label>CMV infection</arm_group_label>
    <description>allograft recipient with active CMV infection</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CMV Infection</intervention_name>
    <description>Routine follow-up (viral load, creatininaemia, neutrophil count, isolation of CMV strains when possible) and biological sample collection for . Resistance testing towards any antiviral available by genotype and phenotype (when an isolate is obtained) when resistance criteria are fulfilled. Plasma collection at treatment initiation, and in case of neutropenia, for antiviral dosage.</description>
    <arm_group_label>CMV infection</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Detection of the CMV in sang, the leukocytes, or plasma with or without the viral
      quantification and/or the sample of urine of saliva or tissues, positive for research of
      CMV.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        allograft recipient or hematopoietic stem cell or solid organ.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  allograft recipient with active CMV infection,

          -  or patient from the previous cohort, without opposition to biological collection of
             samples

        Exclusion Criteria:

          -  not willing to participate, no health insurance
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sophie ALAIN, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Limoges UH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sophie ALAIN, MD</last_name>
    <phone>05 55 05 67 28</phone>
    <email>sophie.alain@unilim.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sébastien HANTZ, MD</last_name>
    <phone>05 55 05 86 42</phone>
    <email>sebastien.hantz@unilim.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Virologie</name>
      <address>
        <city>Amiens</city>
        <zip>80</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>GAUDIO CASTELAIN Sandrine, MD</last_name>
      <phone>03 22 82 79 25</phone>
      <email>Sandrine.Castelain@u-picardie.fr</email>
    </contact>
    <investigator>
      <last_name>GAUDIO CASTELAIN Sandrine, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virologie</name>
      <address>
        <city>Angers</city>
        <zip>49</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandra DUCANCELLE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alexandra DUCANCELLE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virologie</name>
      <address>
        <city>Besancon</city>
        <zip>25</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>COAQUETTE Alain, MD</last_name>
      <phone>03 81 21 88 80</phone>
      <email>alain.coaquette@ufc-chu.univ-fcomte.fr</email>
    </contact>
    <investigator>
      <last_name>COAQUETTE Alain, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virologie - Hôpital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <zip>93</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>DENY Paul, MD</last_name>
      <phone>01 48 95 56 10</phone>
      <email>paul.deny@avc.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>DENY Paul, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virologie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>GARRIGUE Isabelle, MD</last_name>
      <phone>05 56 79 55 10</phone>
      <email>isabelle.garrigue@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>GARRIGUE Isabelle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virologie</name>
      <address>
        <city>Brest</city>
        <zip>29</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie VALLET, MD</last_name>
    </contact>
    <investigator>
      <last_name>Sophie VALLET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virologie</name>
      <address>
        <city>Caen</city>
        <zip>14</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>GOUARIN Stéphanie, MD</last_name>
      <phone>02 31 27 25 56</phone>
      <email>gouarin-s@chu-caen.fr</email>
    </contact>
    <investigator>
      <last_name>GOUARIN Stéphanie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virologie</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PEIGUE-LAFEUILLE Hélène, MD</last_name>
      <phone>04 73 17 81 43</phone>
      <email>helene.lafeuille@u-clermont1.fr</email>
    </contact>
    <investigator>
      <last_name>PEIGUE-LAFEUILLE Hélène, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HP - Hôpital Beaujon - Virologie</name>
      <address>
        <city>Clichy</city>
        <zip>92118</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent MACKIEWICZ, MD</last_name>
    </contact>
    <investigator>
      <last_name>Vincent MACKIEWICZ, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HP - Hôpital MONDOR - Virologie</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Michel PAWLOTSKY, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Michel PAWLOTSKY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virologie</name>
      <address>
        <city>Dijon</city>
        <zip>21</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BOUR Jean-Baptiste, MD</last_name>
      <phone>03 80 29 38 56</phone>
      <email>jbbour@u-bourgogne.fr</email>
    </contact>
    <investigator>
      <last_name>BOUR Jean-Baptiste, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virologie</name>
      <address>
        <city>Grenoble</city>
        <zip>38</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>GERMI Raphaële, MD</last_name>
      <phone>04 76 76 56 04</phone>
      <email>RGermi@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>GERMI Raphaële, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Chirurgical Marie Lannelongue</name>
      <address>
        <city>Le Plessis Robinson</city>
        <zip>92350</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine MOUGEOT, MD</last_name>
    </contact>
    <investigator>
      <last_name>Christine MOUGEOT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virologie</name>
      <address>
        <city>Lille</city>
        <zip>59</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>DEWILDE Anny, MD</last_name>
      <phone>03 20 44 51 46</phone>
      <email>adewilde@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>DEWILDE Anny, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bactériologie Virologie</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ALAIN Sophie, MD</last_name>
      <phone>05 55 05 67 24</phone>
      <email>sophie.alain@unilim.fr</email>
    </contact>
    <investigator>
      <last_name>ALAIN Sophie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virologie</name>
      <address>
        <city>Lyon</city>
        <zip>69</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MORFIN Florence, MD</last_name>
      <phone>04 78 77 70 26</phone>
      <email>florence.morfin-sherpa@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>MORFIN Florence, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HCLYON - Virologie - Hôpital La Croix Rousse</name>
      <address>
        <city>Lyon</city>
        <zip>69314</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick ANDRE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Patrick ANDRE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virologie - AP-HM - La Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine ZANDOTTI, MD</last_name>
    </contact>
    <investigator>
      <last_name>Christine ZANDOTTI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virologie</name>
      <address>
        <city>Montpellier</city>
        <zip>34</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SEGONDY Michel, MD</last_name>
      <phone>04 67 33 71 27</phone>
      <email>m-segondy@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>SEGONDY Michel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virologie</name>
      <address>
        <city>Nancy</city>
        <zip>54</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>VENARD Véronique, MD</last_name>
      <phone>03 83 15 34 71</phone>
      <email>v.venard@chu-nancy.fr</email>
    </contact>
    <investigator>
      <last_name>VENARD Véronique, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virologie</name>
      <address>
        <city>Nantes</city>
        <zip>44</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Céline BRESSOLLETTE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Céline BRESSOLLETTE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virologie</name>
      <address>
        <city>Nimes</city>
        <zip>30</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CHARACHON Sylvie, MD</last_name>
      <phone>04 66 68 32 02</phone>
      <email>sylvie.charachon@chu-nimes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virologie - Hôpital La Pitié Salpétrière</name>
      <address>
        <city>Paris</city>
        <zip>75</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David BOUTOLLEAU, MD</last_name>
    </contact>
    <investigator>
      <last_name>David BOUTOLLEAU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virologie - Hôpital BICHAT</name>
      <address>
        <city>Paris</city>
        <zip>75</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadira HOUHOU, MD</last_name>
    </contact>
    <investigator>
      <last_name>Nadira HOUHOU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virologie - Hôpital SAINT-LOUIS</name>
      <address>
        <city>Paris</city>
        <zip>75</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Christine MAZERON, MD</last_name>
    </contact>
    <investigator>
      <last_name>Marie-Christine MAZERON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virologie - Hôpital NECKER</name>
      <address>
        <city>Paris</city>
        <zip>75</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LERUEZ-VILLE Marianne, MD</last_name>
      <phone>01 44 49 62 64</phone>
      <email>marianne.leruez@nck.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>LERUEZ-VILLE Marianne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HP - Hôpital Saint-Antoine - Virologie</name>
      <address>
        <city>Paris</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joël GOZLAN</last_name>
    </contact>
    <investigator>
      <last_name>Joël GOZLAN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HP - Hôpital TENON - Virologie</name>
      <address>
        <city>Paris</city>
        <zip>75970</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick SOUSSAN, MD</last_name>
    </contact>
    <investigator>
      <last_name>Patrick SOUSSAN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HP - Hôpital Georges Pompidou - Virologie</name>
      <address>
        <city>Paris</city>
        <zip>75908</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ali SI MOHAMED, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ali SI MOHAMED, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virologie</name>
      <address>
        <city>Poitiers</city>
        <zip>86</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BEBY-DEFEAUX Agnès, MD</last_name>
      <phone>05 49 44 38 15</phone>
      <email>a.beby-defaux@chu-poitiers.fr</email>
    </contact>
    <investigator>
      <last_name>BEBY-DEFEAUX Agnès, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virologie</name>
      <address>
        <city>Reims</city>
        <zip>51</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fanny RENOIS, MD</last_name>
    </contact>
    <investigator>
      <last_name>Fanny RENOIS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virologie</name>
      <address>
        <city>Rennes</city>
        <zip>35</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MINJOLLE CHA Sophie, MD</last_name>
      <phone>02 99 28 42 76</phone>
      <email>Sophie.minjolle@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>MINJOLLE CHA Sophie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virologie</name>
      <address>
        <city>Rouen</city>
        <zip>76</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>GUEUDIN Marie, MD</last_name>
      <phone>02 32 88 82 36</phone>
      <email>marie.gueudin@chu-rouen.fr</email>
    </contact>
    <investigator>
      <last_name>GUEUDIN Marie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virologie</name>
      <address>
        <city>Saint-etienne</city>
        <zip>42</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvie PILLET, MD</last_name>
    </contact>
    <investigator>
      <last_name>Sylvie PILLET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virologie</name>
      <address>
        <city>Strasbourg</city>
        <zip>67</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samira FAFI-KREMER, MD</last_name>
    </contact>
    <investigator>
      <last_name>Samira FAFI-KREMER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virologie</name>
      <address>
        <city>Toulouse</city>
        <zip>31</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MENGELLE Catherine, MD</last_name>
      <phone>05 67 69 04 19</phone>
      <email>mengelle.c@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>MENGELLE Catherine, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virologie</name>
      <address>
        <city>Tours</city>
        <zip>37</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>GAUDY Catherine, MD</last_name>
      <phone>02 47 47 16 58</phone>
      <email>gaudy_c@med.univ-tours.fr</email>
    </contact>
    <investigator>
      <last_name>GAUDY Catherine, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virologie - Hôpital Paul Brousse</name>
      <address>
        <city>Villejuif</city>
        <zip>94</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>VAGHEFI Parissa, MD</last_name>
      <phone>01 45 59 30 57</phone>
      <email>parissa.vaghefi@pbr.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>VAGHEFI Parissa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 17, 2014</lastchanged_date>
  <firstreceived_date>February 14, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Transplantation</keyword>
  <keyword>CMV infection</keyword>
  <keyword>antiviral resistance</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cytomegalovirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antiviral Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
